Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroPace Inc.

10.41
-0.1900-1.79%
Post-market: 10.410.00000.00%19:21 EDT
Volume:273.09K
Turnover:2.87M
Market Cap:341.43M
PE:-12.56
High:10.73
Open:10.60
Low:10.38
Close:10.60
Loading ...

Cantor Fitzgerald Remains a Buy on NeuroPace (NPCE)

TIPRANKS
·
16 Jun

NeuroPace Inc. Conducted Annual Stockholders' Meeting Virtually

Reuters
·
13 Jun

UBS Reaffirms Their Buy Rating on NeuroPace (NPCE)

TIPRANKS
·
12 Jun

Analysts Offer Insights on Healthcare Companies: MAIA Biotechnology, Inc. (MAIA) and NeuroPace (NPCE)

TIPRANKS
·
09 Jun

BRIEF-Neuropace Inc - Enters Into Credit Agreement With Midcap Funding Iv Trust

Reuters
·
05 Jun

Neuropace Inc - Enters Into Credit Agreement With MidCap Funding Iv Trust - SEC Filing

THOMSON REUTERS
·
05 Jun

Neuropace Secures up to $75 Million in Debt Financing

THOMSON REUTERS
·
05 Jun

Neuropace Inc - Proceeds Used to Repay Term Loan With Crg Partners

THOMSON REUTERS
·
05 Jun

Press Release: NeuroPace Secures Up to $75 Million in Debt Financing

Dow Jones
·
05 Jun

Cantor Fitzgerald Sticks to Their Buy Rating for NeuroPace (NPCE)

TIPRANKS
·
02 Jun

NeuroPace Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
28 May

Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal

TIPRANKS
·
28 May

NeuroPace initiated with a Buy at H.C. Wainwright

TIPRANKS
·
28 May

Neuropace, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $18

THOMSON REUTERS
·
28 May

Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential

TIPRANKS
·
28 May

NeuroPace’s Promising Prospects: Buy Rating Affirmed Despite Initial Study Setback

TIPRANKS
·
27 May

Leerink says NeuroPace results disappointing, sees hope on totality of data

TIPRANKS
·
27 May

Neuropace Shares Fall 22.5% After Co's Epilepsy Implant Fails to Meet Main Efficacy Goal in Study

THOMSON REUTERS
·
27 May

BUZZ-NeuroPace falls after epilepsy implant fails to meet main study goal

Reuters
·
27 May

NeuroPace Says Epilepsy Trial Meets Safety Goal, Misses Overall Efficacy Target

MT Newswires Live
·
27 May